1.Bone marrow involvement by primary oxalosis
Stefano FRATONI ; Pasquale NISCOLA
Blood Research 2020;55(4):192-192
2.Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
Pasquale NISCOLA ; Carmen Di GRAZIA ; Carla MAZZONE ; Barbara TOLU ; Paolo DE FABRITIIS ; Emanuele ANGELUCCI
Blood Research 2019;54(4):288-290
No abstract available.
Azacitidine
;
Decitabine
;
Leukemia, Myeloid, Acute
;
Salvage Therapy
;
Myelodysplastic Syndromes
3.Hematologists and nephrologists working together: moving forward with a new integrated care model for blood-related malignancies?.
Pasquale NISCOLA ; Tommaso CARAVITA ; Paola TATANGELO ; Agostina SINISCALCHI ; Paolo DE FABRITIIS ; Roberto PALUMBO
Blood Research 2017;52(3):218-219
No abstract available.
4.Steroid-refractory immune thrombocytopenia in the era of the new thrombomimetic drugs: is there still a role for rituximab?.
Massimiliano PALOMBI ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Malgorzata Monika TRAWINSKA ; Pasquale NISCOLA ; Paolo DE FABRITIIS
Blood Research 2016;51(1):66-66
No abstract available.
Thrombocytopenia*
;
Rituximab
5.Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab.
Andrea TENDAS ; Pasquale NISCOLA ; Laura SCARAMUCCI ; Luca CUPELLI ; Alessio Pio PERROTTI ; Paolo DE FABRITIIS
Blood Research 2016;51(2):137-138
No abstract available.
Red-Cell Aplasia, Pure*
;
Rituximab*
6.Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia.
Pasquale NISCOLA ; Andrea TENDAS ; Roberta MEROLA ; Giulia ORLANDI ; Laura SCARAMUCCI ; Paolo DE FABRITIIS
Blood Research 2015;50(3):181-182
No abstract available.
Anemia, Refractory*
;
Azacitidine*
;
Erythropoietin*
;
Leukemia, Myelomonocytic, Chronic*
7.Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Stefano FRATONI ; Paolo DE FABRITIIS
Blood Research 2015;50(2):113-114
No abstract available.
Azacitidine*
;
Humans
8.Pure erythroid leukemia in advanced breast cancer.
Pasquale NISCOLA ; Andrea TENDAS ; Mauro MINELLI ; Alessio PERROTTI ; Paolo DE FABRITIIS ; Giovanni DEL POETA
Blood Research 2014;49(1):69-72
No abstract available.
Breast Neoplasms*
;
Breast*
;
Leukemia*
9.Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Daniela PICCIONI ; Paolo DE FABRITIIS
Blood Research 2014;49(1):65-66
No abstract available.
Leukemia, Myeloid, Acute*
;
Leukemia, Myelomonocytic, Chronic*
10.Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Roberta MEROLA ; Gianfranco CATALANO ; Paolo DE FABRITIIS
Blood Research 2014;49(2):130-137
No abstract available.
Humans
Result Analysis
Print
Save
E-mail